GENEVA, July 18 -- BEIJING SUNGEN BIOMEDICAL TECHNOLOGY CO., LTD. filed a patent application (CN2026/071133) for “ANTI-CCR8 ANTIBODY AND ANTI-CCR8/CTLA-4 BISPECIFIC ANTIBODY, AND USE THEREOF”. With publication no. WO/2026/149434, here are the other details related to the patent application:
Kind: Initial Publication with ISR [A1]
IPC: C07K 16/28
Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).
Disclaimer: Curated by HT Syndication....